Skip to content

CROI 2020 TB Round Up

  • Dorrit Walsh
Treatment Action Group welcomes the flurry of tuberculosis (TB) data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). This statement includes a summary of major findings, TAG’s take on them, and a more detailed overview of key findings.
Read more
Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape report cover

Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape

  • Dorrit Walsh
Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.
Read more

An Activist’s Guide to the LAM Test

  • Chad Cipiti

Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…

Read more
Image of page one: TAG Update 2019

2019 TAG Update

  • Dorrit Walsh
TAG’s work in 2019 demonstrated our leadership towards an end to HIV, hepatitis C, and tuberculosis through hard-hitting, science-based activism. Excerpts of the media coverage we received walk you through a remarkable year of TAG’s work.
Read more
Back To Top